DOHA, Qatar, April 10, 2017 /PRNewswire/ -- On April 4, 2017, two Doha, Qatar-based medical facilities, Hamad General Hospital, a publicly-run facility, and a newly-opened private hospital under the aegis of Sidra Medical and Research Center, successfully completed the first implantation of the Venus P-valve, a proprietary trans-catheter self-expanding pulmonary artery valve developed by Venus Medtech (Hangzhou) Inc. This is the first clinical implantation in Qatar following the product's gaining of approval from the European health and supervision bureau for CE clinical trials in 2016. The implantations signal a significant deepening of Venus Medtech's global footprint. On April 4 and 5, four complicated cases were completed successfully.
The first to be operated on using the valve was a 12 year-old female patient who had been diagnosed with severe pulmonary regurgitation after a radical operation for Tetralogy of Fallot with pulmonary atresia, causing undue strain on the patient's right ventricle. The plan was to perform a trans-catheter implantation using the Venus P-valve to treat the regurgitation issue. The operation was performed jointly by Drs. Ziyad Hijazi and Qi-Ling Cao, two leading cardiac intervention specialists. After the operation, Dr. Hijazi said: "The design of the Venus P-valve gave us the stability in terms of release and the accuracy in terms of positioning. We can use this valve with more patients. I'm very pleased with the functioning of the valve used in the case."
The Venus Medtech Venus P-valve trans-catheter pulmonary artery valve, a self-expanding valve device and matching valve ring with a 16-32 mm internal diameter and a bilateral trumpet-shaped design enabling a surgical procedure free of a pre-placed stent, is by far the only choice for patients worldwide with right ventricular outflow tract regurgitation after a right ventricular outflow tract patch procedure.
Prof. Shakeel Qureshi from UK-based Evelina London Children's Hospital is the Principal Investigator (PI) for the CE Mark clinical trail for the Venus P-valve in Europe, the first phase of a series of clinical trials taking place in 8 locations and involving nearly 80 patients across Europe, including a few locations outside of the continent.
Hangzhou, China-based Venus Medtech focuses their R&D on internationally advanced interventional artificial heart valve systems with commercial applications.
More information: www.venusmedtech.com [http://www.venusmedtech.com/].
Venus Medtech (Hangzhou) Inc.
CONTACT: Juan Wu, +86-10-5272-3093, email@example.com